ArticleScientific reports2026
Integration of multi-omics and single-cell analysis reveals ZBP1 as a prognostic biomarker of renal cell carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ZBP1 in Neuroinflammation and Neurodegeneration: Z-Nucleic-Acid Sensing, RHIM Signalling and Therapeutic Targeting.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Z-DNA binding protein 1 (ZBP1) is a critical factor that induces various forms of cell death and inflammatory responses. However, it has not been comprehensively analyzed in malignancies. The present study aimed to elucidate the oncogenic role of ZBP1 in human malignancies and examine its prospective function in renal cell carcinoma. The pathogenic significance of ZBP1 in malignancies was clarified using a multi-omics analysis and single-cell analysis utilizing bioinformatics methods. The function of ZBP1 in renal cell carcinoma was validated using in vivo and in vitro studies. In this study, we proved that ZBP1 high expression was significantly correlated with worse prognosis in kidney renal clear cell carcinoma and acute myeloid leukemia. Elevated ZBP1 levels correlated with cancer-associated fibroblast invasion. Furthermore, the single-cell analysis revealed that ZBP1 was significantly expressed in CD4+ T cells, CD8+ T cells, and regulatory T cells. ZBP1 may participate in cancer by regulating the inflammatory pathways. Cellular tests demonstrated that downregulating ZBP1 expression significantly inhibited renal cell carcinoma cell proliferation, migration, and invasion. The transplanted tumor model indicated that suppressing ZBP1 expression significantly reduced tumor progression. ZBP1 is a promising biomarker related to the prognosis of pan-cancer, especially renal cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.